Dexamethasone Intravitreal Implant (Ozurdex®) for Recurrent Vogt-Koyanagi-Harada (VKH) Disease Posterior Uveitis

Long Term Efficacy of Dexamethasone Intravitreal Implant (Ozurdex®) in Treatment of Recurrent VKH Uveitis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03971279

Enrollment

Registered

2019-06-03

Start date

2017-01-01

Completion date

2019-11-22

Last updated

2019-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posterior Uveitis

Keywords

dexamethasone;VKH

Brief summary

VKH disease is a vision threatening condition.The investigators consider that ozurdex intravitreal implant is an effective line of treatment in recurrent VKH posterior uveitis.

Detailed description

Baseline ,and postoperative 1 ,6 ,12 and 24 months full ophthalmic examination was done. Procedure included intravitreal injection of Dexamethasone implant 0.7 mg (Ozurdex(®); Allergan, Inc, Irvine, CA)

Interventions

DRUGDexamethasone Ophthalmic implant

intravitreal injection of ozurdex implant

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Recurrent VKH posterior uveitis

Exclusion criteria

* retinal pathology, other causes of posterior uveitis

Design outcomes

Primary

Measure	Time frame	Description
Best corrected visual acuity (BCVA)	2 years	Change in BCVA

Secondary

Measure	Time frame	Description
optical coherence tomography (OCT) foveal thickness	2 years	changes in central foveal thickness

Countries

United Arab Emirates

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026